𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?

✍ Scribed by David Marin; Jamshid S. Khorashad; Letizia Foroni; Dragana Milojkovic; Richard Szydlo; Alistair G. Reid; Katayoun Rezvani; Marco Bua; John M. Goldman; Jane F. Apperley


Book ID
108676251
Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
60 KB
Volume
145
Category
Article
ISSN
0007-1048

No coin nor oath required. For personal study only.